Todays Report: The Illumina Inc. (ILMN) Given Neutral Rating at BTIG Research

The Illumina Inc. (ILMN) Given Neutral Rating at BTIG Research

BTIG Research reissued their neutral rating on shares of Illumina Inc. (NASDAQ:ILMN) in a research report released on Wednesday morning.

A number of other research firms have also issued reports on ILMN. JPMorgan Chase & Co. raised their target price on shares of Illumina from $185.00 to $200.00 and gave the company an overweight rating in a research note on Wednesday, July 27th. Cantor Fitzgerald reissued a hold rating on shares of Illumina in a report on Wednesday, June 29th. Vetr downgraded shares of Illumina from a buy rating to a hold rating and set a $187.86 price target for the company. in a report on Monday. Argus increased their price target on shares of Illumina from $175.00 to $185.00 and gave the company a buy rating in a report on Monday, August 8th. Finally, Mizuho increased their price target on shares of Illumina from $138.00 to $148.00 and gave the company a neutral rating in a report on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $157.50.

Shares of Illumina (NASDAQ:ILMN) traded down 0.606% during midday trading on Wednesday, hitting $135.355. 383,418 shares of the company were exchanged. The stock’s 50-day moving average is $172.97 and its 200-day moving average is $156.29. The stock has a market cap of $19.84 billion, a PE ratio of 46.354 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. During the same period last year, the business posted $0.80 EPS. Illumina’s revenue was up 11.3% compared to the same quarter last year. Equities research analysts anticipate that Illumina will post $3.53 EPS for the current year.

In other Illumina news, SVP Charles Dadswell sold 8,632 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $155.00, for a total value of $1,337,960.00. Following the transaction, the senior vice president now directly owns 40,248 shares in the company, valued at $6,238,440. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 10,000 shares of the company’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $150.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the director now owns 498,061 shares in the company, valued at $74,709,150. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Patten & Patten Inc. TN bought a new position in Illumina during the third quarter valued at approximately $211,000. Fox Run Management L.L.C. bought a new position in Illumina during the third quarter valued at approximately $509,000. Terra Nova Asset Management LLC bought a new position in Illumina during the third quarter valued at approximately $620,000. Eagle Asset Management Inc. bought a new position in Illumina during the third quarter valued at approximately $22,528,000. Finally, Creative Planning increased its position in Illumina by 29.2% in the third quarter. Creative Planning now owns 26,275 shares of the life sciences company’s stock valued at $4,773,000 after buying an additional 5,932 shares in the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Illumina Company Profile

Related posts

Leave a Comment